Hot
News
In patients with recurrent or refractory FL who had previously received third-line or more systematic treatment, the overall remission rate (ORR) was 91%, and the complete remission rate (CR) was 77%. After 24 months of treatment, 56% of patients were still in remission.
June 25, 2022 / bioon/ -- BMS recently announced that the U.S. Food and Drug Administration (FDA) has approved the CD19 car-t cell therapy breyanzi (lisocabtagene maraleucel, LISO CEL)
June 14, 2022 / BIOON / -- Novartis recently announced the long-term results of Eliana, a key clinical study of CD19 car-t cell therapy kymriah (tisagenlecleucel).
